Clinical Trial · NCT05289193

CD8+ Cell Imaging During Neoadjuvant ImmunoTherapy (The C-IT Neo Trial)

Overview

Combination treatment with nivolumab and ipilimumab before surgery may help people with melanoma because the drugs are designed to help the immune system target and destroy cancer cells (immunotherapy), which may shrink the cancer and prevent recurrence after surgery. Treatment given before surgery is called neoadjuvant therapy. The purpose of this study is to find out whether neoadjuvant therapy with nivolumab and ipilimumab can kill melanoma tumors before surgery and prevent disease from coming back after surgery. This study also explores a new, experimental PET scan that images the immune system to see if it is related to treatment outcomes.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

Phase 2

Contacts

Michael Postow, MD (Principal Investigator)

postowm@mskcc.org

646-888-4589

Neeta Pandit-Taskar

pandit-n@mskcc.org

2126393046

ClinicalTrials.gov

NCT05289193

Drug / Compound

Isotope(s):
Target(s):